Loren Carroll, MD
Family Medicine · Jackson, TNNPI 1104168178
Payments from drug & device makers
Across 296 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$887
- Novo Nordisk$864
- Otsuka America Pharmaceutical, Inc.$420
- Lilly USA, LLC$351
- GSK$351
- AstraZeneca$331
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,28998%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $887 |
| Novo Nordisk | 50 | $864 |
| Otsuka America Pharmaceutical, Inc. | 22 | $420 |
| Lilly USA, LLC | 24 | $351 |
| GSK | 22 | $351 |
| AstraZeneca | 13 | $331 |
| Pfizer | 18 | $282 |
| Teva Pharmaceuticals USA, Inc. | 10 | $282 |
| Amgen | 14 | $219 |
| Sumitomo Pharma America, Inc. | 5 | $179 |
| Lundbeck LLC | 10 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $160 |
| Dexcom, Inc. | 5 | $106 |
| Ardelyx, Inc. | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| SK Life Science, Inc. | 3 | $69 |
| Nestle Healthcare Nutrition Inc. | 3 | $67 |
| Merck | 4 | $58 |
| Astellas Pharma US Inc | 2 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Eisai Inc. | 2 | $39 |
| Novartis | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Neurelis, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| MDD US Operations, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$104
How this compares
$5,400 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,184 | $495,811 |
| AustedoDeutetrabenazine | 88 | $176,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 242 | $168,421 |
| OzempicSemaglutide | 139 | $137,965 |
| NuplazidPimavanserin Tartrate | 38 | $92,225 |
| JanuviaSitagliptin Phosphate | 283 | $86,307 |
| FarxigaDapagliflozin Propanediol | 189 | $80,479 |
| LinzessLinaclotide | 138 | $78,898 |
| XareltoRivaroxaban | 355 | $77,198 |
| TrulicityDulaglutide | 115 | $54,587 |
| Austedo XrDeutetrabenazine | 22 | $52,998 |
| NuedextaDextromethorphan Hbr/Quinidine | 113 | $49,013 |
| MyrbetriqMirabegron | 279 | $48,816 |
| MounjaroTirzepatide | 44 | $48,229 |
| RexultiBrexpiprazole | 128 | $47,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $282 | $527,3672,290 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $282 | $229,811110 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $864 | $206,002349 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $351 | $183,909270 claims |
| AbbVieLinzess, Ubrelvy, Vraylar, Qulipta | $887 | $136,888205 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $331 | $114,810244 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $351 | $102,816159 claims |
| MerckJanuvia | $58 | $86,307283 claims |
| Johnson & JohnsonXarelto | $16 | $77,198355 claims |
| Boehringer IngelheimJardiance, Tradjenta | $20 | $69,211348 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $48,816279 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $420 | $47,940128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Jackson
- Kellie Wallace-WildingJackson$93K
- Grant StudebakerJackson$27K
- Elizabeth LondinoJackson$17K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.